# The Use of Broadly Neutralizing Antibodies in HIV-1 Treatment and Prevention

**ID:** BNAB-003
**Year:** 2024
**Journal:** Viruses (MDPI)
**DOI:** [10.3390/v16060911](https://www.mdpi.com/1999-4915/16/6/911)
**PubMed:** [PMC11209272](https://pmc.ncbi.nlm.nih.gov/articles/PMC11209272/)

---

## Abstract

This comprehensive 2024 review examines the current state of broadly neutralizing antibody (bnAb) development for HIV-1 treatment and prevention. It covers the evolution from first-generation antibodies to potent next-generation candidates, combination therapy strategies, long-acting modifications, and the key challenges of pre-existing resistance that must be overcome for clinical success.

---

## Key Concepts

- **bnAbs**: Antibodies capable of neutralizing diverse HIV-1 strains
- **Epitope Targeting**: Conserved sites on HIV envelope (Env)
- **Combination Therapy**: Multiple bnAbs for broader coverage
- **LS Modification**: Fc mutations extending antibody half-life
- **Analytical Treatment Interruption (ATI)**: Testing viral suppression off ART

---

## Evolution of bnAb Development

### Generational Progression
| Generation | Examples | Characteristics |
|:-----------|:---------|:----------------|
| First (1990s) | b12, 2G12 | Limited potency, narrow breadth |
| Second (2010s) | VRC01, PG9, PGT121 | Improved potency, broader coverage |
| Third (2020s) | N6LS, VRC07-523LS | Ultra-potent, enhanced half-life |

### Key Epitopes Targeted
| Epitope | Representative bnAbs | Breadth |
|:--------|:--------------------|:--------|
| CD4 binding site | VRC01, 3BNC117, N6 | ~90% |
| V1V2 apex | PG9, PG16, CAP256-VRC26 | ~70% |
| V3 glycan | PGT121, 10-1074 | ~65% |
| MPER | 10E8, 4E10 | ~98% |
| gp120-gp41 interface | 35O22, 8ANC195 | Variable |

---

## Combination Therapy Studies

### 3BNC117 + 10-1074 Combination
| Finding | Result |
|:--------|:-------|
| Viral suppression in ATI | Up to 43 weeks |
| Delay in rebound (aviremic) | Up to 21 weeks |
| Requirement | No resistant strains at baseline |
| Key factor | ART initiation during acute infection |

### Population Sensitivity
| bnAb | Sensitive (%) |
|:-----|:--------------|
| 3BNC117 | 67% |
| 10-1074 | 58% |
| Both antibodies | **50%** |

> "Only 50% of chronically infected, virologically suppressed people living with HIV harbor virus sensitive to both 3BNC117 and 10-1074."

---

## Long-Acting Modifications

### LS Mutation Technology
| Modification | Effect |
|:-------------|:-------|
| M428L/N434S (LS) | 3-4x extended half-life |
| M252Y/S254T/T256E (YTE) | Enhanced FcRn binding |
| Half-life | 4-6 weeks â†’ 12-16 weeks |

### LS-Modified bnAbs in Development
| Antibody | Target | Status |
|:---------|:-------|:-------|
| VRC01LS | CD4bs | Phase II complete |
| 3BNC117-LS (GS-5423) | CD4bs | Phase II ongoing |
| 10-1074-LS (GS-2872) | V3 glycan | Phase II ongoing |
| N6LS | CD4bs | Phase I complete |
| VRC07-523-LS | CD4bs | Clinical development |

---

## Current Clinical Trials (2024)

### ACACIA Study
| Parameter | Details |
|:----------|:--------|
| Registry | NCT06205602 |
| Design | Randomized, double-blind, placebo-controlled |
| Intervention | Long-acting bnAb combination at ART initiation |
| Population | Adults with HIV-1 in Sub-Saharan Africa |
| Started | January 2024 |

### Combination with Vaccines
- ChAdV and MVA-vectored conserved mosaic T-cell vaccines
- TLR7 agonist vesatolimod
- 3BNC117-LS + 10-1074-LS combination
- Goal: Functional cure studies

---

## Challenges and Limitations

### Pre-Existing Resistance
| Challenge | Impact |
|:----------|:-------|
| Viral diversity | Single bnAb coverage 50-90% |
| Baseline resistance | 30-50% may be resistant |
| Escape mutations | Rapid emergence under pressure |
| Screening required | Pre-treatment sensitivity testing |

### Practical Considerations
| Factor | Current State |
|:-------|:--------------|
| Administration | IV infusion (inconvenient) |
| Cost | High (antibody production) |
| Frequency | Every 4-16 weeks |
| Resistance testing | Not standardized |

---

## Future Directions

### Optimal Combination Strategies
> "An approach integrated Long Short-Term Memory (LSTM) networks and variational autoencoders to accelerate HIV drug discovery, including optimization of bnAb combinations."

### Emerging Approaches
1. **Trispecific antibodies**: Single molecule targeting 3 epitopes
2. **Bispecific formats**: CD4bs + V3 glycan combinations
3. **AAV-delivered bnAbs**: Gene therapy for continuous expression
4. **Vaccine-elicited bnAbs**: Germline-targeting immunogens

---

## Relevance to Project

bnAb research informs the Ternary VAE project:
- **Epitope mapping**: Conserved regions as sequence constraints
- **Resistance prediction**: Modeling escape mutations
- **Fitness landscapes**: Trade-offs between neutralization sensitivity and replication
- **Envelope evolution**: Tracking bnAb-induced selection pressure

---

*Added: 2025-12-24*
